Interleukin-15 increases myosin accretion in human skeletal myogenic cultures

Cell Biology International

Volumn 27, Issue 10, 2003, Pages 845-851

  Furmanczyk, Paul S ^a   Quinn, LeBris S ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Anabolism; Atrophy; Cytokines; Hypertrophy; Insulin like growth factor I; Interleukin 15; Muscle fibers; Myoblasts; Myotubes; Skeletal muscle

Indexed keywords

GROWTH FACTOR; MUSCLE PROTEIN; MYOSIN; MYOSIN HEAVY CHAIN; RECOMBINANT INTERLEUKIN 15; RECOMBINANT SOMATOMEDIN C;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FETUS; HUMAN; HUMAN CELL; MUSCLE CELL; MUSCLE DEVELOPMENT; MYOBLAST; PROTEIN SYNTHESIS; SKELETAL MUSCLE; STEM CELL; STIMULATION; TARGET CELL;

RODENTIA;

EID: 0141788640     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1065-6995(03)00172-0     Document Type: Article

References (27)

1. Adams G.R., Haddad F. The relationships among IGF-I, DNA content, and protein accumulation during skeletal muscle hypertrophy. J Appl Physiol. 81:1996;2509-2516.
2. Adams G.R., McCue S.A. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 84:1998;2509-2516.
3. Barton-Davis E.R., Shoturma D.I., Musaró A., Rosenthal N., Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A. 95:1998;15603-15607.
4. Carbó N., López-Soriano J., Costelli P., Busquets S., Alvarez B., Baccino F.M., et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer. 83:2000;526-531.
5. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 270:1995;12109-12116.
6. Damon S.E., Haugk K.L., Birnbaum R.S., Quinn L.S. Retrovirally mediated overexpression of insulin-like growth factor binding protein 4: Evidence that insulin-like growth factor is required for skeletal muscle differentiation. J Cell Physiol. 175:1998;109-120.
7. Florini J.R., Ewton D.Z., Coolican S.A. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev. 17:1996;481-517.
8. Friedlander A.L., Butterfield G.E., Moynihan S., Grillo J., Pollack M., Holloway L., et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 86:2001;1496-1503.
9. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:1994;965-968.
10. Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:2000;1-9.
11. Haugk K.L., Wilson H.M.-P., Swisshelm K., Quinn L.S. IGF binding protein-related protein-1: An autocrine/paracrine factor which inhibits skeletal myoblast differentiation but permits proliferation in response to IGF. Endocrinol. 141:2000;100-110.
12. Hirschberg R., Kopple J., Lipsett P., Benjamin E., Minei J., Albertson T., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 55:1999;2423-2432.
13. Kotler D.P. Cachexia. Ann Intern Med. 133:2000;622-634.
14. Lamberts S.W.J., van den Beld A.W., van der Lely A.J. The endocrinology of aging. Science. 278:1997;419-424.
15. Lieberman S.A., Butterfield G.E., Harrison D., Hoffman A.R. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 78:1994;404-410.
16. Musaró A., McCullagh K., Paul A., Houghton L., Dobrowolny G., Molinaro M., et al. Localized Igf-I transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 27:2001;195-200.
17. Papadakis M.A., Grady D., Black D., Tierney M.J., Gooding G.A.W., Schambelan M., et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 124:1996;708-716.
18. Phelan J.N., Gonyea W.J. Effect of radiation on satellite cell activity and protein expression in overloaded mammalian skeletal muscle. Anat Rec. 247:1997;179-188.
19. Quinn L.S., Steinmetz B., Maas A., Ong L.D., Kaleko M. Type-1 IGF receptor overexpression produces dual effects on myoblast proliferation and differentiation. J Cell Physiol. 159:1994;387-398.
20. Quinn L.S., Haugk K.L., Grabstein K.H. Interleukin-15: A novel anabolic cytokine for skeletal muscle. Endocrinol. 136:1995;3669-3672.
21. Quinn L.S. Cellular and molecular mechanisms of growth hormone action on skeletal muscle: Implications for treatment of age-associated sarcopenia. J Anti-Aging Med. 5:2002;19-32.
22. Quinn L.S., Anderson B.G., Drivdahl R.H., Alvarez B., Argilés J.M. Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: Implications for treatment of muscle wasting disorders. Exp Cell Res. 280:2002;55-63.
23. Rosenblatt J.D., Yong D., Parry D.J. Satellite cell activity is required for hypertrophy of overloaded adult rat muscle. Muscle Nerve. 17:1994;608-613.
24. Takala J., Ruokenen E., Webster N.R., Nielsen M.S., Zandstra D.F., Vundelinckx G., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 341:1999;785-792.
25. Tisdale M.J. Biology of cachexia. J Natl Cancer Inst. 89:1997;1763-1773.
26. Waters D., Danska J., Hardy K., Koster F., Qualls C., Nickell D., et al. Recombinant human growth hormone, insulin-like growth factor I, and combination therapy in AIDS-associated wasting. Ann Intern Med. 125:1996;865-872.
27. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:2000;1472-1489.